### Seeing positive consumption trends; Maintain Neutral

We recently participated in Gillette India Ltd. (GILL's) Investors & Analysts Call held by the management to highlight company's performance, strategies and business outlook. Key takeaways: 1) Seeing positive consumption trends with greenshoots in rural markets but cautious about unemployment and wages data, 2) GILL has seen 1.5x increase in its reach & coverage in last 3 years, 3) Male grooming continues to see highest ever share even in competitive market environment, 4) Within the large female hair removal market, razors have seen fastest growth and Venus has doubled its revenues in last 5 years growing in double digits, 5) Gill saw structural margin improvement of ~200bps in recent quarter through productivity and innovations. We recently (post the June'24 quarterly results) downgraded the stock to NEUTRAL rating from BUY after it delivered ~63% post our initiation on 30<sup>th</sup> Aug 2023. Information provided during the analyst meet does not lead to any change in our earnings or TP, hence we maintain our TP of Rs9,035, targeting ~56x on Sep'26E EPS (similar to its 5yr avg fwd. multiple).

#### Key pointers from Gillette India's Investors Analysts Meet 2024:

- Macro: Positive trends are finally emerging in consumption with greenshoots in rural. Lower inflation and strong monsoons augur well for rural consumption. Declining rural wages and unemployment are still a concern.
- Male Grooming: GILL has continued to be the market leader with the highest ever market share in a market environment with increased competitive intensity. Blades & Razors category stands at Rs3.3bn growing in mid-single digit. Company acknowledges the change in category with trend towards beards, but it is driving or maintaining high shares with innovations like *Fusion* (redesigned as re-styling tool).
- Female Grooming: Female grooming is a large market in which GILL focuses on inhome hair removal and competes with creams and salons. Razors have seen the highest growth on the back of convenience in a fast-paced life with lesser time to remove hair. In the past 5 years, *Venus* has double its revenues and has grown in double digits.
- **Oral care:** Growth in toothbrush has been slow for GILL due to competitive intensity in the entry level portfolio. Company recently upgraded the packaging so that the consumer easily identifies in a cluttered shelf space. It expects mid-single digit growth for the segment.
- Appliances contribute to 2% of the category in India. Braun has the best technology globally when it comes to shaving and trimming. The products are primarily available on e-commerce and digital platforms.
- Electric toothbrush: The company continued to strengthen the portfolio across all ages. Launched electric brushes with lower price points.
- Distribution: Reach & coverage increased by ~1.5x for the grooming category over the last 3 years. Company developed in-house AI & ML to predict consumption which has helped them significantly reduce dead stocks.
- Innovations: In FY24, GILL launched *Gillette Labs* razor and Venus Bikini Sensitive razor. Company also rolled upgraded Gillette Guard priced at Rs 12 supported by superior compelling advertisement for Hindi heartland. Introduced toothbrushes for kids in partnership with 'Chota Bheem'.
- **A&SP:** The spends were significantly higher in FY24 and was function of business need, innovations and consumer awareness support. When a superior product enters the market, the company does aggressive A&SP to create awareness, which was the case in FY24.
- Structural margin improvement of ~200bps in FY24 was driven by productivity as well as product innovation for consumers to trade up.
- Productivity: Company saw savings of Rs450mn in FY24 owing to productivity.
- **P&G Shiksha**: Program now completing 20 years, touching 1,000 schools & communities, impacting 45+ lacs students.




Reco	:	NEUTRAL
СМР	:	Rs 9,006
Target Price	:	Rs 9,035
Potential Return	:	+0.3%

#### **Stock data** (as on Sep 18, 2024)

Nifty	25,378
52 Week h/l (Rs)	9495 / 5916
Market cap (Rs/USD mn)	289907 / 3464
Outstanding Shares (mn)	33
6m Avg t/o (Rs mn):	222
Div. yield (%):	1.1
Bloomberg code:	GILL IN
NSE code:	GILLETTE

#### Stock performance



### Shareholding pattern (As of Jun'24 end) Promoter 75.0%

TIONIOLOI	75.070
FII+DII	13.9%
Others	11.1%

#### $\Delta$ in stance

(1-Yr)	New	Old
Rating	NEUTRAL	NEUTRAL
Target Price	9,035	9,035

# ∆ in earnings estimates FY25e FY26e FY27e EPS (New) 140.5 157.3 173.3

EPS (New)	140.5	157.3	173.3
EPS (Old)	140.5	157.3	NA
% Change	0.0%	0.0%	NA

### Financial Summary (June-ending)

i manciai eamina	indicial earling, (saile chang,							
(Rs mn)	FY25E	FY26E	FY27E					
Revenue	28,489	30,696	32,999					
YoY Growth (%)	8.2	7.7	7.5					
EBIDTA	6,779	7,549	8,281					
Margins (%)	23.8	24.6	25.1					
PAT	4,578	5,126	5,648					
EPS	140.5	157.3	173.3					
YoY Growth (%)	11.2	12.0	10.2					
ROCE (%)	63.6	70.0	74.9					
ROE (%)	47.0	51.9	55.6					
P/E (x)	64.1	57.3	52.0					
EV/EBITDA (x)	43.1	38.7	35.2					

VISHAL PUNMIYA Lead Analyst vishal.punmiya@ysil.in



MANAS RASTOGI, Associate




#### We also attended Procter & Gamble Hygiene and Health Care Limited (PGHH) Investors Analysts Meet September 2024. Key pointers:

- Feminine Care: PGHH expects double digit category growth over the next 3 years for the Feminine care category led by penetration and consumption. It is a market leader with nearly half of the market share. The Feminine care market is about Rs3.4bn which has seen 100x rise in the last 30 years. Penetration levels lag in rural which stands at 40% vs urban at 60%. However, value spent per consumer is just 1/6th of China in urban markets. D2C has grown in niche channels but form less than 10% of category.
- Innovations: FY24 saw the strongest innovation pipeline for the company to drive category growth (Whisper Ultra XL, Vicks Roll-on, Steam Pods, Double Power Vicks Cough Drops and Period Panties).
- PGHH has grown its coverage by 1.5x in healthcare and 1.2x in Fem Care in the last few years.
- It has comprehensive plans to address the huge demand during Festive season for both rural and urban markets.
- PGHH saw ~400bps improvement in margin structure in latest quarter, but deliberately invested back into the business.


### **STORY IN CHARTS (GILLETTE INDIA)**

Exhibit 1: Revenues are expected to reach Rs33bn growing at a CAGR of 7.8% over FY24-27E




Source: Company, YES Sec


### Exhibit 2: Grooming and Oral care revenue mix are likely to remain stable at 81% and 19% respectively by FY27E



### Exhibit 3: Grooming segment revenues expected to reach Rs27bn by FY27E



### Exhibit 4: Oral care segment revenues estimated at ~Rs6bn by FY27E



For important information about YES Securities (India) Ltd. and other disclosures, refer to the end of this material.




expansion to 58% by FY27E..

**Gillette India Ltd.** 




Exhibit 5: Gross margin expected to see ~150bps

### Exhibit 6: ..EBITDA margins are expected to improve by 130bps to 25.1% over FY24-27E




### Exhibit 7: A&SP was Rs3.6bn, higher by 340bps YoY at 13.8% in FY24 to support innovations




Source: Company, YES Sec

## Exhibit 8: Grooming segment EBIT margin up by ~340bps to 22.7% in FY24



# Exhibit 9: Oral segment EBIT margin moderated by 240bps to 12.9% in FY24



Source: Company, YES Sec



CAGR of 9.7% over FY24-27E






Exhibit 10: EBITDA is expected to reach Rs8.3bn at a

### Exhibit 11: APAT would reach Rs5.6bn at a CAGR of 11.1% over FY24-27E



Source: Company, YES Sec


# Exhibit 12: Free cash flow would reach Rs6.2bn by FY27E



Source: Company, YES Sec

Source: Company, YES Sec

### Exhibit 13: ROE and ROCE (pre-tax) expected to reach 55.6% and 74.9% respectively by FY27E




For important information about YES Securities (India) Ltd. and other disclosures, refer to the end of this material.



### **View & Valuation**

- We expect revenues to grow in grow by ~8.2% in FY25E on a base of ~6.3% led by 1) Continued momentum in grooming segment with an added support from value portfolio as we anticipate rural volume recovery in near-term, 2) Growth recovery in oral care on lower base, 3) Exports recovery in FY25.
- Over FY24-27E, we estimate 7.8% revenue CAGR. Our current growth estimates do not consider any major reversal in trend towards shaving from 'sporting beard' or 'trimming'.
- Gross margin recovery was ahead of expectation in FY24, leading to beat on operating margin. Over FY24-27E, we now build ~130bps improvement in EBITDA margin largely led by pricing+premiumization and productivity interventions leading to EBITDA growth of 9.7% over FY24-27E.
- Gillette's market share are at highest levels and continue to gain. With strong traction in Gillette Labs, upgraded Guard product and continued innovations, it's market share should further improve or atleast be maintained in a competitive environment.
- The company boasts strong return ratios and has also shown healthy growth in dividends over the years.
- We recently (post the June'24 quarterly results) downgraded the stock to NEUTRAL rating from BUY after it delivered ~63% post our initiation on 30th Aug 2023. It is currently trading at ~64x/57x/52x June'25/June'26/June'27E EPS. Information provided during the analyst meet does not lead to any change in our earnings or target price (TP), hence we maintain our TP of Rs9,035, targeting ~56x on Sep'26E EPS (similar to its 5yr avg fwd. multiple).



#### Exhibit 14: Currently trading at ~62x 1-yr forward earnings



### **FINANCIALS**

### **Exhibit 15: Balance Sheet**

Y/E June (Rsmn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	326	326	326	326	326
Reserves	9,563	9,387	9,430	9,686	9,968
Net worth	9,889	9,713	9,756	10,012	10,294
Total debt	0	0	0	0	0
Deferred tax liability and others	-458	-535	-535	-535	-535
Total liabilities	10,545	10,182	10,225	10,482	10,764
Gross block	8,029	8,430	9,180	9,930	10,680
Depreciation	4,134	4,961	5,841	6,797	7,827
Net block	3,895	3,469	3,339	3,133	2,853
Capital work-in-progress	324	259	500	500	500
Investments	0	0	0	0	0
Other LTA	1986	2178	2493	2239	2556
Inventories	4,124	3,958	4,871	4,067	5,428
Debtors	3,202	2,743	3,189	2,867	3,462
Cash	4,556	4,756	4,661	5,244	6,083
Other current assets	591	383	383	383	383
Total current assets	12,499	11,866	13,129	12,585	15,382
Creditors	6,801	6,390	7,873	6,428	8,764
Other current liabilities & provisions	1,357	1,200	1,363	1,548	1,762
Total current liabilities	8,158	7,590	9,235	7,976	10,526
Net current assets	4,341	4,276	3,894	4,610	4,856
Total assets	10,545	10,182	10,225	10,482	10,764

Source: Company, YES Sec

### **Exhibit 16: Income statement**

Y/E June (Rsmn)	FY23	FY24	FY25E	FY26E	FY27E
Revenue	24,771	26,331	28,489	30,696	32,999
% Growth	9.8%	6.3%	8.2%	7.7%	7.5%
COGS	11,881	11,013	12,395	13,049	13,863
Staff costs	1,698	1,874	2,080	2,272	2,409
Advertising costs	2,916	3,629	3,678	3,978	4,293
Other expenses	2,884	3,541	3,557	3,848	4,154
Total expenses	19,379	20,057	21,710	23,147	24,718
EBITDA	5,392	6,274	6,779	7,549	8,281
% growth	11.8%	16.4%	8.0%	11.4%	9.7%
EBITDA margin (%)	21.8%	23.8%	23.8%	24.6%	25.1%
Other income	222	261	290	322	357
Interest costs	78	86	70	65	60
Depreciation	807	826	880	955	1,030
Profit before tax (before exceptional items)	4,729	5,623	6,118	6,851	7,547
Тах	1,172	1,506	1,540	1,724	1,900
PAT (before exceptional items)	3,557	4,117	4,578	5,126	5,648
PAT	3,557	4,117	4,578	5,126	5,648
PAT margin (%)	14.4%	15.6%	16.1%	16.7%	17.1%
% Growth	22.9%	15.8%	11.2%	12.0%	10.2%



### **Exhibit 17: Cash flow statement**

Y/E June (Rsmn)	FY23	FY24	FY25E	FY26E	FY27E
PAT	3,557	4,117	4,578	5,126	5,648
Depreciation	807	826	880	955	1,030
Net other income	-222	-261	-290	-322	-357
(Inc.)/dec. in working capital	190	265	287	-133	594
Cash flow from operations	4,409	5,034	5,525	5,692	6,975
Capital expenditure (-)	-746	-336	-991	-750	-750
Net cash after capex	3,663	4,698	4,535	4,942	6,225
Inc./(dec.) in investments	219	175	477	79	545
Cash from investing activities	-527	-161	-514	-671	-205
Dividends paid (-)	-2,314	-4,399	-4,349	-4,870	-5,365
Inc./(dec.) in total borrowings	76	-273	-70	-65	-60
Cash from financial activities	-2,238	-4,672	-4,419	-4,935	-5,425
Opening cash balance	2,911	4,556	4,756	4,661	5,244
Closing cash balance	4,556	4,756	4,661	5,244	6,083
Change in cash balance	1,645	201	-95	583	839


Source: Company, YES Sec

### **Exhibit 18: Growth and Ratio matrix**

Y/E June	FY23	FY24	FY25E	FY26E	FY27E
Per share (Rs)					
EPS	109.1	126.3	140.5	157.3	173.3
Book value	303.4	298.0	299.3	307.2	315.9
DPS	85.0	135.0	133.4	149.4	164.6
Valuation (x)					
P/Sales	11.8	11.1	10.3	9.6	8.9
EV/sales	11.8	11.1	10.2	9.5	8.8
EV/EBITDA	54.1	46.5	43.1	38.7	35.2
P/E	82.5	71.3	64.1	57.3	52.0
P/BV	29.7	30.2	30.1	29.3	28.5
Return ratios (%)					
RoCE (pre-tax)	52.0	58.2	63.6	70.0	74.9
RoE	38.5	42.0	47.0	51.9	55.6
RoIC (pre-tax)	81.7	100.6	115.3	134.5	162.6
Profitability ratios (%)					
Gross margin	52.0	58.2	56.5	57.5	58.0
EBITDA margin	21.8	23.8	23.8	24.6	25.1
EBIT margin	3.3	3.1	3.1	3.1	3.1
PAT margin	14.4	15.6	16.1	16.7	17.1
Liquidity ratios (%)					
Current ratio	1.5	1.6	1.4	1.6	1.5
Quick ratio	1.0	1.0	0.9	1.1	0.9
Turnover ratios					
Total asset turnover ratio (x)	1.3	1.5	1.5	1.7	1.5
Fixed asset turnover ratio (x)	6.4	7.6	8.5	9.8	11.6
Debtor days	42	41	38	36	35
Inventory days	121	134	130	125	125
Creditor days	188	219	210	200	200



### **Recommendation Tracker**





#### STANDARD DISCLAIMER:

YES Securities (India) Limited, Registered Address: 2<sup>nd</sup> Floor, North Side, YES BANK House, Off Western Express Highway, Santacruz East, Mumbai - 400055. Maharashtra, India | Correspondence Add: 7<sup>th</sup> Floor, Urmi Estate Tower A, Ganpatrao Kadam Marg, Opp. Peninsula Business Park, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. | Website: www.yesinvest.in | Email: customer.service@ysil.in

Registration Nos.: CIN: U74992MH2013PLC240971 | SEBI Registration No.: NSE, BSE, MCX & NCDEX : INZ000185632 | Member Code: BSE – 6538, NSE – 14914, MCX – 56355 & NCDEX – 1289 | CDSL & NSDL: IN-DP-653-2021 | RESEARCH ANALYST: INH000002376 | INVESTMENT ADVISER: INA000007331 | Sponsor and Investment Manager to YSL Alternates Alpha Plus Fund (Cat III AIF) and YES Wealth Maximiser AIF (Cat III AIF) SEBI Registration No.: IN/AIF3/20- 21/0818 | AMFI ARN Code – 94338

Details of Compliance Officer: Aditya Goenka | Email: compliance@ysil.in / Contact No.: 022-65078127 | Grievances Redressal Cell: customer.service@ysil.in / igc@ysil.in

Standard Disclaimer: Investment in securities market are subject to market risks; read all the related documents carefully before investing. Above representation provides an overview related to our past performance neither does it provide any guarantee of future performance, nor we are ensuring any guaranteed returns. Actual Client returns may vary depending upon time premium, volatility Index, intrinsic value of the script, open interest, other geopolitical conditions and choice of the customer to execute the recommendation in full or part. All recommendations are published under Research Analyst License of YES Securities (India) Limited (YSIL); execution of the recommendation is at complete discretion of customer without any intervention by the research publisher.

Contents which are exclusively for Non-Broking Products/Services e.g. Mutual Fund, Mutual Fund-SIP, Research reports, Insurance, etc. where the YSIL is just a distributor. These are not Exchange traded product and the YSIL is just acting as distributor. Kindly note that all disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism.

YSIL is a wholly owned subsidiary of YES Bank Limited. Savings, Current, PIS and Demat Account are offered by YES Bank Limited. Please note Brokerage would not exceed the SEBI prescribed limit. YSIL also acts in the capacity of distributor for Products such as IPOs, Mutual Funds, Mutual Fund-SIPs, NCD/Bonds, etc., All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism.

Margin Trading Funding (MTF) is an exchange approved product offered to YSIL trading account holders, as per the regulation and guideline of SEBI Circular: CIR/MRD/DP/54/2017 dated June 13, 2017. For product specification, T&C, rights and obligations statement issued by the YSIL visit https://yesinvest.in/standard\_documents\_policies

#### DISCLAIMER

Investments in securities market are subject to market risks, read all the related documents carefully before investing.

The information and opinions in this report have been prepared by YSIL and are subject to change without any notice. The report and information contained herein are strictly confidential and meant solely for the intended recipient and may not be altered in any way, transmitted to, copied or redistributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of YSIL.

The information and opinions contained in the research report have been compiled or arrived at from sources believed to be reliable and have not been independently verified and no guarantee, representation of warranty, express or implied, is made as to their accuracy, completeness, authenticity or validity. No information or opinions expressed constitute an offer, or an invitation to make an offer, to buy or sell any securities or any derivative instruments related to such securities. Investments in securities are subject to market risk. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. Investors should note that Price of each of the securities or value may rise or fall and, accordingly, investors may even receive amounts which are less than originally invested. The investor is advised to take into consideration all risk factors including their own financial condition, suitability to risk return profile and the like, and take independent professional and/or tax advice before investing. Opinions expressed are our current opinions as of the date appearing on this report. Investor should understand that statements regarding future prospects may not materialize and are of general nature which may not be specifically suitable to any particular investor. Past performance may not necessarily be an indicator of future performance. Actual results may differ materially from those set forth in projections. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. YES Securities (India) Limited conforms with the rules and regulations enumerated in the Securities and Exchange Board of India (Research Analysts) Regulations, 2014 as amended from time to time.

Technical analysis reports focus on studying the price movement and trading turnover charts of securities or its derivatives, as opposed to focussing on a company's fundamentals and opinions, as such, may not match with reports published on a company's fundamentals.

YSIL, its research analysts, directors, officers, employees and associates accept no liabilities for any loss or damage of any kind arising out of the use of this report. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject YSIL and associates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.



YES Securities (India) Limited distributes research and engages in other approved or allowable activities with respect to U.S. Institutional Investors through Rule 15a-6 under the Securities Exchange Act of 1934 (the "Exchange Act")<sup>[1]</sup> and regulations under an exclusive chaperone arrangement with Brasil Plural Securities LLC. The views and sentiments expressed in this research report and any findings thereof accurately reflect YES Securities (India) Limited analyst's truthful views about the subject securities and or issuers discussed herein. YES Securities (India) Limited is not registered as a broker-dealer under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and is not a member of the Securities Investor Protection Corporation ("SIPC"). Brasil Plural Securities LLC is registered as a broker-dealer under the Exchange Act and is a member of SIPC. For questions or additional information, please contact Gil Aikins (gil.aikins@brasilplural.com) or call +1 212 388 5600.

This research report is the product of YES Securities (India) Limited. YES Securities (India) Limited is the employer of the research analyst(s), the authors of this research report. YES Securities (India) Limited is the concerned representatives (employees) of YES Securities (India) Limited, are responsible for the content of this research report including but not limited to any material conflict of interest of YES Securities (India) Limited in relation the issue(s) or securities as listed in this research report. This YES Securities (India) Limited in relation the united States through Brasil Plural Securities (LC (BPS). The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and is/ are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities theld by a research analyst account. As per SEC Rule 15a-6, the U.S. broker-dealer must accompany any third party research report it distributes with, or provide a web address that directs a recipient to, disclosure of any material conflict of interest that can reasonably be expected to have influenced the choice of a third-party research report report provider or the subject company of a third-party research.

FINRA Rules 2241 and 2242, which govern the conduct of research analysts and the content of equity and debt research reports, respectively, apply to all research distributed by a FINRA member firm, including research prepared by a foreign broker-dealer under Rule 15a-6.

- Research reports prepared by a foreign broker-dealer and distributed by a U.S. broker-dealer are deemed to be third
  party research reports, as reports produced by a person other than a FINRA member.
- Prior to distributing any third party research, a U.S. broker-dealer must assure that such report contains the required disclosures under FINRA Rule 2241(h) or 2242(g)(3), as applicable.

This report is intended for distribution by YES Securities (India) Limited only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). As per Rule 15a-6(b)(4) of the Exchange Act, 1934, "Major U.S. institutional investor" means a U.S. institutional investor with assets, or assets under management, in excess of US\$100 million, or a registered investment adviser with assets under management in excess of US\$100 million. If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person or entity. Transactions in securities discussed in this research report should be effected through Brasil Plural Securities LLC (BPS) or another U.S. registered broker dealer/Entity as informed by YES Securities (India) Limited from time to time.

- (a) Effecting unsolicited securities transactions;
- (b) Providing research reports to major U.S. institutional investors, and effecting transactions in the subject securities with or for those investors;
- (c) Soliciting and effecting transactions with or for U.S. institutional investors or major U.S. institutional investors through a "chaperoning broker-dealer"; and
- (d) Soliciting and effecting transactions with or for registered broker-dealers, banks3 acting in a broker or dealer capacity, certain international organizations, foreign persons temporarily present in the U.S., U.S. citizens resident abroad, and foreign branches and agencies of U.S. persons.

In adopting Rule 15a-6, the SEC sought "to facilitate access to foreign markets by U.S. institutional investors through foreign broker-dealers and the research that they provide, consistent with maintaining the safeguards afforded by broker-dealer registration." [Rule 15a-6 Adopting Release at 54 FR 30013; see also Registration Requirements for Foreign Broker-Dealers, Exchange Act Release No. 25801 (June 14, 1988), 53 FR 23645 (June 23, 1988)].

<sup>&</sup>lt;sup>[1]</sup> Rule 15a-6 under the Securities Exchange Act of 1934 provides conditional exemptions from broker-dealer registration for foreign broker-dealers that engage in certain specified activities involving U.S. investors. These activities include:



#### **DISCLOSURE OF INTEREST**

Name of the Research Analyst: Vishal Punmiya, Manas Rastogi

The analyst hereby certifies that opinion expressed in this research report accurately reflect his or her personal opinion about the subject securities and no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendation and opinion expressed in this research report.

Sr. No.	Particulars	Yes/No
1	Research Analyst or his/her relative's or YSIL's financial interest in the subject company(ies)	No
2	Research Analyst or his/her relative or YSIL's actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of the research report	No
3	Research Analyst or his/her relative or YSIL has any other material conflict of interest at the time of publication of the research report	No
4	Research Analyst has served as an officer, director or employee of the subject company(ies)	No
5	YSIL has received any compensation from the subject company in the past twelve months	No
6	YSIL has received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
7	YSIL has received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
8	YSIL has received any compensation or other benefits from the subject company or third party in connection with the research report	No
9	YSIL has managed or co-managed public offering of securities for the subject company in the past twelve months	No
10	Research Analyst or YSIL has been engaged in market making activity for the subject company(ies)	No

Since YSIL and its associates are engaged in various businesses in the financial services industry, they may have financial interest or may have received compensation for investment banking or merchant banking or brokerage services or for any other product or services of whatsoever nature from the subject company(ies) in the past twelve months or associates of YSIL may have managed or co-managed public offering of securities in the past twelve months of the subject company(ies) whose securities are discussed herein.

Associates of YSIL may have actual/beneficial ownership of 1% or more and/or other material conflict of interest in the securities discussed herein.

#### **RECOMMENDATION PARAMETERS FOR FUNDAMENTAL REPORTS**

Analysts assign ratings to the stocks according to the expected upside/downside relative to the current market price and the estimated target price. Depending on the expected returns, the recommendations are categorized as mentioned below. The performance horizon is 12 to 18 months unless specified and the target price is defined as the analysts' valuation for a stock. No benchmark is applicable to the ratings mentioned in this report.

BUY: Upside greater than 20% over 12 months

ADD: Upside between 10% to 20% over 12 months

NEUTRAL: Upside between 0% to 10% over 12 months

REDUCE: Downside between 0% to -10% over 12 months

SELL: Downside greater than -10% over 12 months

NOT RATED / UNDER REVIEW



Analyst signature

#### **ABOUT YES SECURITIES (INDIA) LIMITED**

YES Securities (India) Limited ("YSIL") is a wholly owned subsidiary of YES BANK LIMITED. YSIL is a Securities and Exchange Board of India (SEBI) registered Stock broker holding membership of National Stock Exchange (NSE), Bombay Stock Exchange (BSE), Multi Commodity Exchange (MCX) & National Commodity & Derivatives Exchange (NCDEX). YSIL is also a SEBIregistered Category I Merchant Banker, Investment Adviser and Research Analyst. YSIL is also a Sponsor and Investment Manager of Alternate Investment Fund - Category III (YSIL Alternates) and AMFI registered Mutual Fund Distributor. The Company is also a registered Depository Participant with CDSL and NSDL. YSIL offers, inter alia, trading/investment in equity and other financial products along with various value added services. We hereby declare that there are no disciplinary actions taken against YSIL by SEBI/Stock Exchanges.